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Abstract: The Toll-Like Receptor (TLR) family is appeared to be 
expressed in many cell types in the immune system and plays a role in the 
pathogenesis of various autoimmune diseases. The expression profile and 
role of TLRs in Systemic Sclerosis (SSc) have been partly explained. It is 
aimed through this investigation to evaluate the expression pattern of TLR 
4 and 5 in Peripheral Blood Mononuclear Cells (PBMCs) from SSc 
patients. PBMCs were isolated from whole blood of 20 SSc patients and 50 
healthy individuals. Total RNA content of leukocytes was extracted. Then, 
cDNA was synthesized from the mRNA of the cells. Afterward, 
Quantitative analysis was carried out through Real-Time PCR using the 
TaqMan Gene Expression Assays. An over expression of TLR5 mRNA in 
PBMCs from SSc patients was seen in comparison to healthy individuals. 
Nevertheless, the gene expression of TLR4 in SSc patients remained almost 
equal to controls. Our findings suggest that over expression of TLR5 in SSc 
patients may be involved in the pathogenesis of SSc. 
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Introduction 
Systemic Sclerosis (SSc) is a systemic connective 
tissue disease, characterized by fibrosis of the skin and 
internal organs, injuries of the small arteries 
(microangiopathy) and the presence of autoantibodies 
(Varga and Abraham, 2007). A pathogenic role in the 
SSc has been suggested through interactions between 
modified endothelial cells and cells of immune system in 
eliciting changed fibroblast functional (Jimenez and 
Derk, 2004). Furthermore, interplay between 
environmental factors and genetic modification is 
thought to be contributing factor in the SSc (Tan and 
Arnett, 2000). Fibroblasts in SS are distinguished by 
high amount of collagen synthesis and excess fibrotic 
condition over degradation is thought to take place 
(Pattanaik et al., 2015). 
Toll-Like Receptors (TLRs) are a group of type I 
integral membrane glycoproteins, which almost 11 families 
of them have been described in human (Botos et al., 
2011). TLRs play an essential role in the innate immune 
system as Pathogen-Recognition Receptors (PRRs) to 
recognize conserved structures within microbes known 
as Pathogen-Associated Molecular Patterns (PAMPs) 
and self-cells derived Damage-Associated Molecular 
Patterns (DAMPs) (Janeway Jr, 1992). Several DAMPs 
in distinct pathogens are recognized by TLRs that leads 
to a signaling cascade and results in production of 
various pro-inflammatory cytokines, chemokines and 
type I IFNs (Akira et al., 2006). 
Regarding to several autoimmune diseases, 
endogenous ligands or pathogens-activated immune cells 
and even fibroblasts and endothelial cells in SSc, have 
become more plausible to have role in such disease. 
Circulating TLR4 ligands have been identified in serum 
of SSc patients (Roelofs et al., 2005). Ligation of TLR4 
can induce an increased production of IL-10 in 
monocyte-derived Dendritic Cells (moDCs) from SSc 
patients. Taking interleukin (IL)-10 production is related 
with the increased level of profibrotic CC Chemokine 
Ligand (CCL)-18, a profibrotic role for TLR-activated 
moDCs can be implied (van Lieshout et al., 2009). TLR4 
has been shown to play a role in SSc patients and 
monocytes from SSc patients with interstitial lung 
disease have an enhanced pro-fibrotic phenotype. These 
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monocytes can differentiate into fibrocytes and secrete 
collagen in higher amounts after exposure to the LPS, 
the TLR4 agonist (Mathai et al., 2010). Moreover, 
activation of fibroblast TLR4 signaling, triggered by 
damage-associated endogenous TLR4 ligands, results in 
increased transforming growth factor-β1 sensitivity with 
increased matrix production and progressive connective 
tissue remodeling. Accordingly, fibroblast TLR4 serves 
as the switch for converting self-limited tissue repair into 
intractable fibrosis (Bhattacharyya et al., 2013). On the 
other side, TLR5 shows increment in SSc fibroblasts and 
may have a suppressive impression on collagen 
expression. Presumably, the over expression of TLR5 in 
SSc fibroblasts is a negative response against tissue 
fibrosis (Sakoguchi et al., 2013). 
TLRs pathway and overactivity, especially TLR4, 
have been related to SSc immunopathogenesis through 
involvement in secretion of chemokines and 
cytokines. Furthermore, the over expression of TLR4 
and 5 genes among patients with SSc has already been 
observed. Given the before evidences, in this study we 
aimed to assess expression levels of TLR4 and 5 in 
Peripheral Blood Mononuclear Cells (PBMCs), of SSc 
patients as a confirmatory investigation of expression 
profile of these molecules. 
Subjects and Methods 
Patients and Healthy Control Subjects 
The patients were recruited from Firouzgar Hospital 
Rheumatology Department and diagnosed as having 
systemic sclerosis according to the American College of 
Rheumatology criteria for SSc (LeRoy et al., 1988). 
Twenty SSc patients and 50 healthy age- and sex-
matched healthy volunteers were included in the study 
(Table 1). Patients had received no immunomodulatory 
therapy for at least 3 months before they were included 
in the study. Moreover, SSc patients who were 
suspicious of other plausible autoimmune disorders 
were excluded. None of the healthy controls had 
autoimmune diseases in neither themselves nor their 
immediate family members. The Human Research 
Ethics Committees from the Tehran University of 
Medical Sciences approved this study. Written 
informed consent was taken by all participants. Blood 
samples from SSc patients were obtained during 
clinical diagnosis; as such, samples were obtained from 
healthy controls. About 5 mL of blood from each 
subject was collected in EDTA-anticoagulated tubes 
and ESR blood collection test tubes using venipuncture.  
PBMC Preparation and RNA Extraction 
Ficoll-Hypaque density gradient centrifugation 
approach was used in order to isolate PBMCs from 
peripheral blood of the subjects. Total cellular RNA 
was extracted using High Pure RNA Isolation Kit 
(Roche, Germany) according to manufacturer’s 
manuals. Yield and purity of RNA were determined 
using a NanoDrop spectrophotometer at 260/280 nm 
(Nano Drop ND-2000 C Spectrophotometer, Thermo 
Fisher Scientific, USA). 
Reverse Transcription and Complementary DNA 
Synthesis 
Complementary DNA (cDNA) was synthesized from 
the RNA of cells using the Transcriptor First Strand 
cDNA Synthesis Kit (Roche, Germany) according to the 
manufacturer’s instruction. Concisely, first 4 µL of 
isolated RNA (30 µg) through previous procedure were 
mixed with 1 µL of random hexamer primer and 7 µL 
RNASe-free H2O and then incubated at 65°C for 5 min. 
Afterwards, micro-tubes were chilled on ice and a 
mixture of reaction buffer 4 µL, RNASe inhibitor 1 µL, 
dNTP mix 2 µL and reverse transcriptase 1 µL was 
added to each sample. Samples were immediately 
incubated at 25°C for 5 min followed by 42°C for 60 
min; the reaction was finally terminated by heating at 
70°C for 5 min. Reverse transcription was performed 
with the final volume of 20 µL pre tube. 
Real-Time Quantitative Polymerase Chain 
Reaction 
Quantitative analysis was carried out by Real Time 
PCR using the TaqMan Gene Expression Assays 
containing the FAM dye-labeled probes (Taq Man Pre-
designed Gene Expression Products, Applied Bio 
systems, Foster City, CA, USA) and StepOnePlus Real-
Time PCR System (Applied Bio systems, Foster City, 
CA, USA). Each reaction mixture contained a total 
volume of 20 µL (master mix 10 µL, cDNA 2 µL [5 ng 
mL], assay mix 1 µL and H2O 7 µL). The Real Time 
PCR conditions were: 50°C for 2 min, 95°C for 10 
min, then 40 cycles of 95°C for 15 sec and 60°C for 1 
min. A widely used approach to represent relative 
gene expression, the comparative CT method, was 
exploited to evaluate expression as previously 
described by (Schmittgen and Livak, 2008). Relative 
amounts of target mRNAs in test samples were 
calculated and normalized to the corresponding Beta-
actin (ACTB) mRNA transcript level as a 
housekeeping gene. Then relative expression for each 
sample was calculated using the following equation: 
Relative mRNA expression = (2
−∆Ct
) ×10
3
. 
Statistical Analysis 
Data analysis was fulfilled via SPSS software version 
18 (SPSS, Chicago, IL, USA). Scale variables were 
calculated for normality using the Kolmogorov-Smirnov 
test. Through the independent sample t-test, group 
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comparisons of continues variables were carried out. If 
the variable was not normally distributed, Mann-
Whitney nonparametric test was conducted. The 
GraphPad Prism version 5.00 for Windows (GraphPad 
Software, La Jolla California USA, www.graphpad.com) 
was applied to illustrate data through graph. All results 
are expressed as mean ± Standard Error of Mean (SEM) 
with statistical significance set at 5%. 
Results 
Demographic traits of SSc patients are listed in the 
Table 1. Case subjects with the mean age of 40.7±6.9 
were found to be age matched with healthy control group 
with that of 42±11.5 (p>0.05). The participants were also 
sex matched and of the 20 SSc patients, 15 (75%) and 5 
(25%) were male and female respectively; healthy 
subjects were consisted of 37 (74%) males and 13 (26%) 
females. A significant difference (p<0.001) was 
observed between ESR values of SSc patients 
(21.26±16.1) and healthy individuals (4.4±3.82). 
No significant difference was observed (fold change 
= 1.11; p = 0.34) in the expression level of TLR4 
between SSc patients and healthy controls (Fig. 1A). 
Nevertheless, PBMCs from SSc patients expressed the 
TLR5 mRNA highly (2.49 times up regulated; p = 
0.011) in comparison to healthy subjects (Fig. 1B).  
 
Table 1. Baseline Specifications of SSc patients (N = 20) 
Characteristic Mean (%) Standard deviation 
Age 42 11.5 
Gender 
Male 15 (75) - 
Female 5 (25) - 
Disease duration 7.05 7.77 
Disease subset 
Limited 14 (70) - 
Diffuse 6 (30) - 
modified Rodnan Skin Score (mRSS) 9.5 6.6 
Forced Vital Capacity (FVC)  2.5 0.9 
Diffusing Capacity for Carbon Monoxide (DLCO) 6.5 2.8 
Fibrosis 
Yes 3 (15) - 
No 17 (85) - 
human Placental Alkaline Phosphatase (hPAP) 30.5 7.9 
Pulmonary Hypertension (PHT) 
Yes 4 (20) - 
No 16 (80) - 
Muscle weakness 
Yes 2 (10) - 
No 18 (90) - 
Myosis 
Yes 1 (5) - 
No 19 (95) - 
Gastrointestinal (GI) involvement 
Yes 16 (80) - 
No 4 (20) - 
Alveolit 
Yes 1 (5) - 
No 19 (95) - 
Pulmonary Arterial Hypertension (PAH) 
No 15 (75) - 
Primary  4 (20) - 
Secondary 1 (5) - 
Kidney involvement 
Yes 3 (15) - 
No 17 (85) - 
Fluorescent Antinuclear Antibodies (FANA) 
Positive 16 (80) - 
Negative 4 (20) - 
Anti-Centromere Antibodies (ACA) Titer 15.7 6 
Anti-topo I (Anti-DNA topoisomerase I) 
Positive 10 (50) - 
Negative 10 (50) - 
Erythrocyte Sedimentation Rate (ESR) 21.26 16.1  
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Table 2. The correlations of the expressions of TLR4 and TLR5 mRNAs in PBMCs fromSSc patients with clinical manifestations 
 TLR4  TLR5 
 ----------------------------------------------- ---------------------------------------------- 
Parameter r P value r P value 
Age -0.214 0.379 0.171 0.485 
ESR 0.244 0.314 0.275 0.255 
mRSS 0.345 0.747 0.125 0.845 
FVC  0.225 0221 0.227 0.350 
DLCO  0101 0.681 -0.112 0.653 
hPAP -0.017 0.946 -0.103 0.596 
ACA Titer -0.210 0.387 -0.175 0.474 
Toll-Like Receptor (TLR), Erythrocyte Sedimentation Rate (ESR), r: Pearson’s Correlation Coefficient, Modified Rodnan Skin 
Score (mRSS), Forced Vital Capacity (FVC), Diffusing Capacity for Carbon Monoxide (DLCO), human Placental Alkaline 
Phosphatase (hPAP), Anti-Centromere Antibodies (ACA) 
 
 
 
Fig. 1. Relative expression of TLR4 (A) and TLR5 (B) mRNA in PBMCs from SSc patients and healthy subjects is illustrated 
through Bar graph (SSc: Systemic Sclerosis, HS: Healthy Subjects) 
 
 
 
Fig. 2. Relative expression of TLR4 (A) and TLR5 (B) mRNA in PBMCs from Limited and Diffuse SSc patients is illustrated 
through Bar graph (SSc: Systemic Sclerosis) 
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Fig. 3. Relative expression of TLR4 (A) and TLR5 (B) mRNA in PBMCs from SSc patients with and without Fibrosisis illustrated 
through Bar graph (SSc: Systemic Sclerosis) 
 
Limited subset SSc patients expressed TLR4 higher (fold 
change = 1.42, p = 0.65) than diffuse subset, but 
expressed TLR5 lower (fold change = 0.86, p = 0.71; 
Fig. 2). Both TLR4 and 5 were down regulated (Fig. 3) 
in SSc patients with fibrosis compared with patients 
without fibrosis but this differences were not statistically 
significant (fold change = 0.97; p = 0.94, fold change = 
0.73; p = 0.41, respectively). 
Clinical specifications of age, ESR, mRSS, FVC, 
DLCO, hPAP and ACA titer of SSc patients correlated 
with neither TLR4 nor TLR5 mRNA expression level 
(Table 2). 
Discussion 
Current concentrations have been drawn toward the 
notion that systemic immune dysregulation is the central 
incident that ultimately may lead to fibroblast activation 
and development of SSc. Toll-like receptors are main 
molecules of innate immune system which recognize 
various DAMPs and PAMPs and relate them to adaptive 
immune system. A thorough immune response needs the 
interaction between both innate and adaptive immune 
systems and revolves around TLRs for activation of 
several pathways. 
Outstanding clinical characteristics of systemic 
sclerosis are progressive fibrosis of the skin and internal 
organs. In the pathological point of view, SSc presents 
core manifestations are inflammation and autoimmunity, 
excessive deposition of Extracellular Matrix (ECM) and 
vasculopathy of small arteries (Varga and Abraham, 
2007). Generally, the ECM contains fibrillins, collagens, 
proteoglycans, matrix molecules and fibroblasts and, 
myofibroblasts, which are pivotal effect or cells in 
development and pathogenesis of SSc (Varga, 2007). 
Transforming growth factor β (TGF-β) can be produced 
and secreted by both resident and infiltrating cells in the 
dermis and can activate fibroblasts and induce 
differentiation into myofibroblasts (Kissin et al., 2006; 
Tomasek et al., 2002). The myofibroblasts, in turn, 
produce even more ECM, causing fibrosis and alongside 
with dermal fibroblasts secret various inflammatory 
cytokines and chemokines, like IL-6 and CCL-2 which 
are important inflammatory mediators in the 
pathogenesis of SSc (Feghali et al., 1994; Distler et al., 
2001). Early skin biopsies of SSc patients show 
infiltration of mononuclear inflammatory cells around 
the vessels. Mononuclear cells through involvement of 
PRRs secret cytokines and chemokines that lead to over 
recruiting of inflammatory cells and promoting of the 
ECM deposition (Fleischmajer et al., 1977). 
Recent studies focused on patients with SSc have 
disclosed a dysregulation of type I interferon (IFN) 
pathways. The presence of a type I IFN signature in 
peripheral blood cells from patients with SSc has been 
described by expression profiling investigations (Tan et al., 
2006). Type I IFNs play role in the regulation and 
modulation of the immune system. Furthermore, they 
can modify several processes in the immune system such 
as differentiation, survival, proliferation and cytokine 
production of various immune cells. One of the 
immunoregulatory functions of IFNs is to stimulate 
immune cells to express the TLRs on themselves. TLRs 
are a group of Pattern Recognition Receptors (PRRs) in 
the innate immune system that sense common molecular 
patterns found on microbes and then initiate key 
inflammatory responses (Takeda and Akira, 2004). TLR 
activation can also trigger production and secretion of 
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various inflammatory mediators like type I IFNs. It has 
been demonstrated that the interaction between TLRs 
and IFNs plays a role in the pathogenesis of autoimmune 
diseases, such as systemic lupus erythematous, which 
shows overlapping autoantibody specificities and 
sometimes overlapping clinical manifestations with SSc 
(Crow et al., 2003; Hua et al., 2006). 
Fineschi et al. (2008) demonstrated that 
autoantibodies in SSc patients, which bind to the surface 
of fibroblasts, might contribute to the pathogenesis of 
SSc. They concluded that fibroblasts-binding 
autoantibodies, through up regulation of production of 
profibrotic and proangiogenic chemokines, in a 
proteasome and TLR4-dependent approach, play a role 
in SSc development (Fineschi et al., 2008). Van 
Lieshout et al. (2009) observed an increased serum level 
of CCL18 in SSc patients compared with healthy 
controls and this chemokine, which was mediated, at 
least partly, via IL-10 after TLR4 stimulation, was 
secreted by monocyte derived dendritic cells. The 
ongoing study investigated expression level of TLR4 
mRNA in the PBMCs of SSc patients. Interestingly, we 
observed that TLR4 was not expressed differently in SSc 
patients compared with healthy subjects. Perhaps TLR4 
on the specific cells other than a general immune cell 
population of PBMCs, such as monocyte derived 
dendritic cells and fibroblasts, contributes to the 
development of SSc. 
Sakoguchi et al. (2013) investigated the expression 
profiles of TLR-related genes in SSc fibroblasts. They 
disclosed that TLR5 and TLR10 expressions were 
increased in SSc fibroblasts both in vitro and in vivo. 
Furthermore, they noted that TLR5 itself might have a 
suppressive impression on collagen expression and 
perhaps the over expression of TLR5 in SSc fibroblasts 
was the negative feedback against tissue fibrosis 
(Sakoguchi et al., 2013). To concord with the evidence, 
in this investigation the expression level of TLR5 was 
realized to be 2.49 times up regulated in PBMCs from 
SSc patients compared with healthy individuals. 
However, probable impression and function of increased 
expression level of TLR4 in PBMCs from SSc patients 
need further studies. 
Even though SSc patients over expressed TLR5 
mRNA, ESR values did not correlate with expression 
level of TLR5 mRNA. This prematurely imply to the 
note that, despite increased expression of TLR5 
suppresses collagen expression, this increment do not 
affect inflammatory situation according to ESR level. 
Furthermore, no correlation was observed between other 
parameters, namely Age, mRSS, FVC, DLCO, hPAP 
and ACA titer and TLR5 expression level. 
Conclusion 
The conclusion to be reached is that, our results 
imply that dysregulation of TLR5 expression, but not 
TLR4, may be associated with disease development in 
SSc patients. Hopefully, based upon beneficial effect of 
TLR5 increased expression in suppression of collagen 
production and increased ECM deposition, further 
studies will provide new strategies for TLR pathway 
intervention drug development to be therapeutic 
approaches for SSc patients. 
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